When treating cancer patients with radiation therapy, the normal tissue in an organ close to the tumour usually receives some dose of radiation. The dose is not of the same intensity throughout the organ. This radiation can cause normal tissue complications, so for treatment planning purposes, it is important to understand the relationship between the distribution of dose intensities in the organ and the occurrence of complications. One general summary measure of the dose effect is obtained by integrating a weighting function (w(d)) over the dose distribution. The weighting function w(d) should be monotone for biological reasons. Because the true shape of w(d) is not known, we estimate it non-parametrically subject to the monotonicity constraint. In our approach w(d) is written as a weighted sum of monotone basis functions. The weights in this sum are formulated as a mixture of point mass at zero and a Gamma random variable. A key feature of our method is that it allows for flat regions through the use of this mixture prior. The model is estimated using a Markov Chain Monte Carlo algorithm. We illustrate our method with data from a head and neck cancer study in which the irradiation of the parotid gland results in loss of saliva flow.
INTRODUCTION
Cancer patients treated with radiation therapy can experience complications that are the consequence of the irradiation of normal tissue in an organ close to the tumour site. There is a large literature on normal tissue complication models (see, for example, [1, 2] ). These models relate the dose received by the normal tissue to the probability of a complication. They are typically motivated by some radio-biological or bio-physical theory and sometimes take into account the physical structure of the normal tissue, e.g. whether it is a serial structure such as the spinal cord, or more homogenous such as the parotid gland [3] . The most commonly used model in treatment planning is the Lyman normal tissue complication probability model [4, 5] . This specific model applies to binary outcomes and specifies the probability of complication as a function of dose, the volume of normal tissue irradiated, and three parameters. In contrast to these models, which tend to be highly parametric, our approach is more non-parametric and not restricted to binary outcomes.
While the tumour site generally receives a fairly homogenous dose, the normal tissue in an organ close to the tumour usually receives a heterogeneous dose. It is possible to compute, for each subject and a given radiation treatment plan, the cumulative dose of radiation received at each location within the organ. This dose distribution is typically represented using the dose-volume histogram (DVH), a plot over dose of the proportion of normal tissue which received that dose. Thus, the DVH is a curve that integrates to 1; however, it does ignore the spatial aspect of the distribution of dose within the organ. In some organs, such as the parotid gland which is relatively homogenous, ignoring the spatial aspect seems to be reasonable. For less homogenous organs, such as the lung, this will be less reasonable but may still be used as an approximation or as a first step in a more complicated analysis taking the spatial component into account. See Figure 1 for an example of two DVH's. Denoting the DVH by p(d), the goal is to find the relationship between the curve p(d) and a scalar complication outcome. Specifically, we are interested in using p(d) as a functional covariate to construct an appropriate summary measure of dose in a regression model for the complication outcome.
Functional data analysis is a branch of statistics concerned with curves, which can be used as a response or a predictor [6] . For the latter, one is interested in estimating the effect of a functional covariate p(d) on a scalar outcome, and the functional form often takes p(d)w(d) dd, where w(d) is an unknown weight function (Chapter 15 of [6] ). We are interested in estimating w(d) to construct a summary measure of p(d) as a good explanatory variable of the outcome. This approach was discussed by Hastie and Mallows [7] , and in the functional generalized linear model of James [8] , where p(d)w(d) dd was included as a covariate in a GLM and a regression spline was used to estimate w(d), and by Zhang et al. [9] for a continuous outcome, where a smoothing spline is used to estimate w(d). However, little work is done for such functional models with a monotonic constraint for w(d) using mixed models. Schipper et al. [10] proposed a generalized monotone functional mixed model (GMFMM), which included p(d)w(d) dd as a covariate in a generalized linear mixed model (GLMM) and estimated w(d) monotonically and non-parametrically using a regression spline. Two special cases are worth noting. If w(d) = d then the summary measure is the mean dose received by the organ. If w(d) = I (d>d 0 ) then the summary measure is the proportion of the organ that receives a dose larger than d 0 .
In this paper, we propose a Bayesian version of the GMFMM in Schipper et al. [10] . The dose effect is summarized as p(d)w(d) dd. Any biologically meaningful estimate of w(d) should be monotone, because increasing dose cannot lead to lower probability or severity of complications. Thus, we propose a Bayesian method for monotonic non-parametric estimation of w(d) within this model framework.
The proposed estimator of w(d) in Schipper et al. [10] is strictly monotone. However, when modelling a dose effect, it is possible that there is no effect within a range of doses. This appears 4645 to be the case for low doses in the saliva flow data we use to illustrate our model. This corresponds to flat regions in w(d), and our Bayesian estimator allows for this, which is not allowed in the formulation of Schipper et al. [10] . We define w(d) as the sum of monotone non-decreasing basis functions each multiplied by a non-negative coefficient. The non-negativity is imposed through priors in a Bayesian model. Similar to the approach of Dunson [11] , we specify a mixture prior for the coefficients, which explicitly allow the function w(d) to be flat, while at the same time imposing the monotonicity constraint. In addition to applying to functional covariates, the model proposed in this paper differs from that of Dunson [11] in that it applies to general distributions and correlated outcome measures. This paper is organized as follows. Section 2 describes the model as well as the mixture prior. Section 3 discusses estimation of the model. In Section 4, the head and neck cancer data are described, and the proposed methods are illustrated. In Section 5, simulation results are presented, followed by discussions in Section 6.
THE MODEL

Generalized monotone functional mixed model
In this section we propose a Bayesian GMFMM, for relating a complication outcome to a dose distribution while accounting for other covariates as well as correlation between multiple nonGaussian responses from the same subject. Let Y i j denote the complication outcome for the jth observation of the ith subject, j = 1, . . . , J ; i = 1, . . . , I . We note that there may be multiple measurements of the complication outcome for a particular subject. In the head and neck cancer example we consider later, the complication outcome is saliva flow, which is measured separately from the two parotid glands of each subject. We assume that conditional on random effects b i , Y i j follows an exponential family distribution with mean i j given by
where g is a canonical link function, and b i represent fixed and random effects with corresponding design matrices X i j and Z i j , p i j (d) is the DVH in the organ of interest with p i j (d) dd = 1, and w(d) is an unknown weight. We assume that the random effects b i are independent and follow a N(0, ) distribution. The marginal likelihood is given by
where f (Y i j |b i ) is the conditional density of Y i j and f (b i ) is the normal density of b i . Overdispersion and correlation between observations from the same subject can be modelled using the random effects b i . We further assume w(d) is a smooth, non-decreasing function with w(0) = 0. The constraint w(0) = 0 is for the sake of identifiability. Specifically, from (1), if includes an intercept term, it will be confounded with any intercept w(0) because this latter term can be pulled out from the integration in (1), since p i j (d) integrates to one. 
Formulation of w(d)
One way to constrain w(d) to be non-decreasing is to define it as the sum of non-decreasing functions. We consider the following formulation:
Here B l (d) are known non-decreasing basis functions, L is the number of basis functions, and the s l are non-negative parameter coefficients. With this definition of w(d), the model discussed in the previous section can be written as a GLMM [12] . In particular,
Many choices are possible for the basis functions, and we consider two here. The first is to use piecewise linear basis functions, considered for example by Neelon and Dunson [13] .
is zero till the beginning of the lth interval, then is linear (with slope 1) in the lth interval, and flat at its maximum value after the lth interval. Under this formulation, the slope of w(d) within interval ( l−1 , l ] is given by s l . The second set of basis functions we use are the I-spline functions [14] . These functions are obtained as the integral of B-spline basis functions, and are thus monotone since the B-splines are non-negative. While both basis functions give continuous estimates, a key feature of the I-Spline basis functions is that they result in a smoother estimate compared to the estimator based on the linear basis functions. Since B l (0) = 0 for all l, w(0) = 0 from (3), for both sets of basis functions.
Prior specification
The coefficients s l are restricted to be non-negative through the prior distributions. Adapting the ideas of Dunson [11] , we propose a mixture prior for s l which imposes the monotonicity constraint on w(d) while at the same time allowing for flat regions. Let l be a latent Bernoulli variable indicating zero or non-zero coefficient and l be a positive continuous random variable. Then define s l , as
Thus, l is the value of s l , given s l is non-zero. Plugging (5) into (4) we obtain
Next we define the priors for l and l as
where Gamma(c 1 , ) denotes a Gamma distribution with mean c 1 / and variance c 1 / 2 . Rather than choosing fixed values for and , we specify hyperpriors to reduce the sensitivity of our conclusions to the chosen values. We choose to set c 1 to a fixed value. If we choose c 1 >1 then the prior for l in (8) will have a non-zero mode. This should prevent non-identifiability arising from very small l with positive l and zero l , both leading to similar values for s l . Choosing c 1 >1 also ensures that the prior for l is log-concave. This allows efficient sampling in the Gibbs sampler, as discussed in Section 3. For the hyperpriors, we assume
We note here that w(d) depends on l , in addition to l . This gives some robustness in the estimated w(d) to the choice of the prior on l . To complete the model specification, we place a vague Normal prior on and an inverse Wishart prior on the covariance matrix . the saliva flow data we discuss in the next section. Thus, we can rewrite (1) by replacing the integration with summation over dose bins as
where d k = (k − 1) (bin width). That is, d k is the left endpoint of the kth bin and p(d k ) is the proportion of normal tissue receiving dose in bin k. Similarly we can also rewrite (6) as
Gibbs sampling can be used to estimate the parameters in this model by iteratively sampling from each of the full conditional distributions. Conditional on and , (12) specifies a GLMM with an offset term of
Gibbs sampling for GLMMs has been discussed by many authors, e.g. Zeger and Karim [15] and Dellaportas and Smith [16] , among others. These methods could be used to sample from the full conditional distributions for , b i , and . The only additional computational work is in computing the value of the offset term at each iteration of the Gibbs sampler.
We now focus on the full conditional distributions for the dose effect parameters l , l , , and . Some of these distributions involve the likelihood
where f (Y i j |b i ) is the density of y i j conditional on b i . Let −v denote the set of all unknown parameters except v, and [a 1 |a 2 ] denote the distribution of a 1 given a 2 . We consider the l first. The full conditional distribution for l is given by
where the proportionality constant can be easily calculated since the l are binary. Next we consider the full conditional for the :
Thus, the full conditional for is a Beta distribution for which standard sampling methods are available.
The full conditional for the l is given by
When l = 0, it is clear from (12) that i j does not contain any terms for l . Thus, the likelihood L is independent of l , and the full conditional is proportional to the prior. Conditional on l = 1, the right-hand side of (12) log-concave function of l [16] . Since we have also specified a log-concave prior (Gamma(c 1 , ) ) for l , the full conditional (16) is log-concave because the product of two log-concave functions is also log-concave. Adaptive rejection sampling may be used to efficiently sample from this distribution [17] .
The full conditional for is given by
Thus, the full conditional for is a Gamma distribution, for which straightforward sampling methods are available. The Gibbs sampling discussed here can be conveniently implemented in the program WinBUGS. Convergence of the Markov chain can be assessed using standard methods.
APPLICATION TO HEAD AND NECK CANCER DATA
Data description
The data come from a head and neck cancer study conducted at the University of Michigan.
Patients with a cancerous tumour in their head or neck were treated with external beam radiation therapy. A common side effect in these patients is loss of saliva flow due to the irradiation of the parotid glands. The parotid glands, of which there are two, one in each cheek, are responsible for producing the majority of a person's saliva. The radiation doses ranged from 0 to 82 and the DVH bin widths are 0.5 Gy, thus K = 164. Figure 1 is an example of the DVH's for the two glands of a particular subject. Saliva flows are obtained at baseline (before radiation therapy) and at 6 months after radiation therapy. At each timepoint, saliva flows are measured from both parotids. The ipsilateral glands (gland on the same side of head as tumour) generally received a much higher dose than the contralateral glands (glands on the opposite side of head as tumour). This can be seen in the example DVH's plotted in Figure 1 . As a consequence, the ipsilateral glands typically had much lower saliva flows. In total, there are 157 saliva flow measurements (with corresponding DVH's) from 82 subjects.
Model description
The units of saliva flow are millilitres per minute, so we use the Poisson distribution as outcome distribution. Since the measured saliva flows are not integers, we multiplied the original flows by 150 and rounded to the nearest integer. Let Y i j denote the (transformed) saliva flow from gland j of subject i.
] denote the unobserved random effects for subject i, assumed to be independently distributed as N(0, ). Further, denote the log of the baseline saliva flow from gland j of subject i by base i j . We assume that, conditional on the random effects b i , the saliva flows follow a Poisson distribution with mean i j given by
where p i j ( ) is the DVH for the jth gland of the ith subject.
M. SCHIPPER, J. M. G. TAYLOR AND X. LIN
To use the prior and hyperprior distributions specified in (7) and (10), we must specify values for c 1 , c 2 , and c 3 . We wish to choose these values so that reasonable prior mass is placed on both linear w(d) (i.e. meandose models) and step function w(d) which correspond to a threshold effect. We use the link between model (18) and the simpler meandose model to aid in setting these values. Specifically, if s 1 = s 2 = · · · = s 20 = s, then some algebra shows that (18) can be rewritten as
We fit this mean dose model to the saliva flow data and obtainŝ = 0. (8) and (10) assign large prior probability to a range of plausible values for l including 0.1 and 2.
The marginal variance of the saliva flows is larger than we would expect from the Poisson assumption and is approximately proportional to the square of the marginal mean. The random effects included as part of the linear predictor approximate this variance structure and account for the overdispersion. The two parameters of on the main diagonal capture overdispersion for the ipsilateral and contralateral glands. We do not constrain them to have the same value. Most of the subjects have two measurements, one from each parotid. The off diagonal element of is the covariance between the two sides within a subject. To fit the model, we use Gibbs sampling implemented in WinBUGS.
Results
We fit the model separately using the piecewise linear and I-spline basis functions to define w(d). The reported results are based on using 20 basis functions (L = 20), but similar results were obtained using 10 or 40 functions. Using only five knots resulted in noticeably different estimates of w(d). For each of the I-spline and linear basis function models, we ran two chains for 200 000 iterations discarding the first 50 000 as burn-in and retaining every 10th iteration thereafter. Thus estimates are based on 30 000 iterations. Trace plots of the parameters were compared between chains and within each chain over iteration to visually assess convergence. The chains mixed relatively rapidly for most parameters but were slowest to mix for l . WinBUGS provides an estimate of the Monte Carlo error of the posterior mean estimate, and at 200 000 iterations the estimated Monte Carlo error is less than 10 per cent of the standard error for each parameter. It took about 4 h to run one chain for 200 000 iterations on a PC. Table I gives posterior mean estimates and 95 per cent credible intervals for the parameters based on the I-spline model. Results were very similar for the linear basis function model. The lower 95 per cent credible bounds for 1,1 and 2,2 are not close to 0, suggesting significant overdispersion for both the ipsilateral and contralateral glands, although it is much larger for the former. The estimated covariance between the two sides ( 1,2 ) does not appear to be significantly different from zero.
The posterior mean estimates of w(d) and their 95 per cent pointwise credible intervals are shown in Figure 2 Schipper et al. [10] . We briefly describe the method here. Starting with an unconstrained regression spline r (d), w(d) is defined as the integral of a positive transformation of r (d) as
where is chosen to be proportional to a Normal density. This formulation of w(d) is used in the same model given in (1), but we fit it using maximum likelihood. It is reassuring that the estimates are similar despite coming from different models and different estimation procedures. The Bayesian estimates of w(d) do not exhibit the poor tail behaviour for the largest doses that is present in the Frequentist estimator. Figure 3 plots for each gland the log proportion change in saliva flow versus the estimated summary measure of the dose effect It is notable in Figure 2 that the estimated w(d) is flat for doses less than 30 Gy. This implies that the parotid gland could be given a uniform dose of 30 Gy with minimal effect on saliva flow. In addition it implies that meandose is not the best way to summarize the DVH. When w(d) is defined using linear basis functions it will be flat in a region ( j−1 , j+k ) only if j = j+1 = · · · = j+k = 0. The posterior probability of this event can easily be calculated as the proportion of draws (after discarding burn in) for which it holds. The posterior probabilities of w(d) being flat in the four quartiles (0, 20), (20, 40) , (40, 60), and (60, 81) are 0.72, 0.19, 0.02, and 0.27, respectively. A weakness of these calculations is that they ignore the size of the non-zero increases in w(d). In particular they make no distinction between large coefficients and small coefficients close to zero.
The same calculations can be done for the I-spline basis functions but are slightly more involved. Rather than one, there are five I-spline basis functions with non-zero slope at any dose and thus we must check whether all five coefficients are zero. As a result, the corresponding probabilities are smaller than those based on the linear basis functions. Using the analysis based on the I-spline basis functions, the posterior probabilities of w(d) being flat in the four quartiles of dose are 0.54, 0.004, 0 and 0.06, respectively. These probabilities are noticeably smaller than those from the analysis using linear basis functions. The reason for the difference is that these calculations dichotomize the basis functions as flat or not flat. At a given dose, however, some of the non-flat I-spline basis functions have large slope while some have very small slopes. This is not an issue for the linear basis functions since they have constant slope in their increasing regions. It is an undesirable property of these calculations for the I-spline functions that, although the estimated function w(d) is similar to that using the linear basis functions, the estimated probabilities of flat 
Goodness of fit
We assess goodness of fit of our model using posterior predictive simulation [18] . In this method we simulate new data y rep from the posterior predictive distribution P(y rep |y). To compare the simulated and observed data we use a discrepancy variable, T (y, ), which will take on large values when the data do not fit the model well. For each draw of , we compute T (y obs , ) and T (y rep , ).
A P-value can be calculated as the proportion of times that T (y rep , ) exceeds T (y obs , ). We use the deviance as a discrepancy variable, where the deviance is defined as
The (18) by plugging in the parameter draws from the posterior distribution. For each of the 15 000 post-burn in samples (of one chain), we used the parameter draws to simulate a vector of Poisson data. We then computed the deviance for the observed data and the simulated data using the posterior parameter draws. In 49 per cent of the samples the deviance from the simulated data was greater than that of the observed data. Another commonly used discrepancy variable is the Pearson Chi-square GOF statistic, calculated
In 36 per cent of the samples the Pearson statistic from the simulated data was larger than that of the observed data. Thus for both of these discrepancy variables, we find no lack of fit.
SIMULATIONS
To evaluate our method, we simulate overdispersed Poisson data with a mean dependent on a sigmoidal shape for w(d). We then estimate w(d) with our method using both the I-spline and piecewise linear basis functions. Specifically, we simulate 50 data sets each with 157 (the number of glands for which we have both dose data and saliva flows) independent Poisson variables with means i given by
where a = 5 and b i ∼ N(0, 1). The DVHs were simulated as truncated normal densities with means drawn uniformly in (5, 76.5) and standard deviations drawn uniformly on (1, 10). For each of the 50 simulated data sets we estimated w(d) − a. Figure 4 shows the mean and the 5th and 95th percentiles of these 50 estimates using I-spline basis functions along with the underlying true value. Similar results were obtained from piecewise linear basis functions. Overall, the method seems to work well with little bias except in the tails. In addition, the percentiles are close together and indicate that the estimated w(d) is reasonably stable.
We also fit the model from Schipper et al. [10] to these same 50 data sets in order to compare the efficiency of the two estimators of w(d). Table II contains the standard deviations of the 50 estimated values of w(d) at various doses for each of the estimators. Despite using a different model and estimation procedure, the standard deviations for the method in Schipper et al. [10] are generally similar to those of the Bayesian models. As expected, the variability of each estimator is highest at 40 Gy where w(d) is changing most rapidly. The variability of the two Bayesian estimators is also generally similar although the linear basis functions lead to more variability near 40 Gy. This is not surprising as the I-spline method has the advantage that the 'true' w(d) used to simulate the data sets was created using 20 I-spline basis functions. We found that all of the methods can give poor estimates at 80 Gy, which is at the edge of the design space.
DISCUSSION
We have presented a flexible method for non-parametric and monotone estimation of a dose effect within a Bayesian GMFMM. Estimation of the model parameters can be accomplished via Gibbs sampling and is implemented in a standard program (WinBUGS). Our general summary measure of the dose effect allows us to estimate what aspect of the dose distribution best predicts
